期刊文献+

重症肌无力的临床和胸腺病理分析(附173例报告) 被引量:1

The clinical and pathologic analysis of 173 cases myasthenia gravis after thymectomy
下载PDF
导出
摘要 目的研究重症肌无力患者胸腺的病理改变、临床分型和分期的临床意义。方法回顾性分析173例行胸腺切除重症肌无力患者的术后病理所见与临床特点。结果173例胸腺组织表现为胸腺增生88例(50.87%),胸腺瘤79例(45.66%),正常胸腺4例(2.31%),胸腺萎缩2例(1.16%);胸腺增生组14例(15.91%)、胸腺瘤16例(20.25%)出现术后肌无力危象;重症肌无力患者Osserman临床分型、Masaoka临床病理分期、病理类型间有一定的相关性;多数重症肌无力患者有一种或多种免疫学指标异常。结论综合分析重症肌无力患者的临床资料,结合免疫学的检测结果,有助于该病的有效防治。 Objective To investigate the pathological changes of thymus for myasthenia gravis,as well as the significance of clinical staging and classification. Methods Pathologic change and clinical symptoms of 173 cases of postthymectomy were retrospectively analyzed. Results Among the 173 cases of thymusectomy, 88 cases had thymic hyperplasia, there were 79 cases thymoma,4 cases of normal thymus and 2 cases of atrophy of thymus gland; 14 cases had mysthenic crisis after thymectomy among the group of thymic hyperplasia. 16 cases had mysthenic crisis after thymectomy for the thymoma.There was some associativity among pathologic categories, Masaoka clinical staging and Osserman clinical types; Most patients had one or many kinds of abnormal indicatrix of immunology. Conclusions For the patients of myasthenia gravis,Biding the immunological results and aggregating analysis of the three documents, myasthenia gravis possibly been effectively prevented and cured.
出处 《现代实用医学》 2008年第8期594-596,614,共4页 Modern Practical Medicine
关键词 重症肌无力 胸腺瘤 病理分析 Myasthenia gravis Thymoma Pathological analysis
  • 相关文献

参考文献15

  • 1Levine GD,Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts[J]. Hum Pathol, 1978,9(5):495-515.
  • 2Rosai J, Sobin LH. Histological typing of tumours of the thymus[M]// World Health Orgnization. International Histological classifi cation of tunours.Berlin:Springerverlag,1999:65-68.
  • 3Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymoma with special reference to their clinical stages[J]. Cancer, 1981,48(4) :2485-2492.
  • 4Monden Y,Nakahara K,Fujii Y,et al. My asthenia gravis in elderly patients[J].Ann Thorac Surg,1985,39(1):433-439.
  • 5Aarli JA, Romi F, Skeie GO, et al. Myasthenia gravis in individuals over 40 [J].Ann NY Acad Sci, 2003, 998(2): 424-431.
  • 6Kohman LJ.Controversies in the man agement of malignant thymoma[J].Chest,1997,112(4 Suppl):296S-300S.
  • 7Gautel M,Lakey A,Barlow DP,et al.Titin antibodies in myastheniagravis: identification of a major immunogenic region oftitin[J]. Neurology, 1993,43(8):1581-1585.
  • 8Mygland A,Aarli A,Matre R,et al. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis[J].J Neurol Neurosurg Psychiatry, 1994,57(7):843-846.
  • 9Limburg PC,The TH, Hummel-Tappel, et al. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1: Relation to clinical parameters in 250 patients [J]. J Neurol Sci, 1983, 58 (3): 357-370.
  • 10Somnier FE. Exacerbation of myasthenia gravis after removal of thymomas [J]. Acta Neurol Scand, 1994, 90 (1): 56-66.

二级参考文献12

  • 1Wekerle H.The thymus in myasthenia gravis.Ann N Y Acad Sci,1993,681:47-55.
  • 2Palace J, Vincent A, Beeson D.Myasthenia gravis: diagnostic and management dilemmas. Curr Opin Neurol, 2001,14:583-589.
  • 3Gautel M, Lakey A, Barlow DP, et al. Titin antibodies in myasthenia gravis:identification of a major immunogenic region of titin.Neurology ,1993,43:1581-1585.
  • 4Mygland A, Aarli JA, Matre R, et al. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis.J Neurol Neurosurg Psychiatry, 1994,57:843-846.
  • 5Tu LH, Cai GY, Zhu XM, et al .Using histochemical methods to study pathological features of hyperplastic thymus and thymoma in patients with myasthenia gravis. Ann N Y Acad Sci,1998,841:427-429.
  • 6Müller-Hermelink HK, Marx A. Pathologic aspects of malignant and benign thymic disorders. Ann Med,1999,31 Suppl 2 :5-14.
  • 7Jaretzki A 3rd.Thymectomy for myasthenia gravis: analysis of controversies--patient management. Neurologist, 2003,9:77-92.
  • 8Drachman DB, Jones RJ, Brodsky RA.Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol, 2003, 53:29-34.
  • 9Sprent J, Kishimoto H. T cell tolerance and the thymus. Ann N Y Acad Sci,1998,841:236-245.
  • 10Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.Nat Med, 2001,7:365-368.

共引文献7

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部